ShockNCT06115473
Epinephrine to Prevent Postintubation Collapse in Shocked ICU Patients
A study testing epinephrine and isotonic fluid in people with Shock, run by Ain Shams University at 1 site in Egypt.
Trial summary
Endotracheal intubation is a lifesaving procedure that is performed in various settings within the hospital or even in the pre-hospital field. However, it can result in serious hemodynamic complications, such as post-intubation hypotension (PIH) and cardiac arrest. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Shock
- What is being tested?
- epinephrine and isotonic fluid
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 44 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Aug 2023to Jan 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- septic patients of either sex above 18 years of age, will need emergent intubation during ICU admission, shock index (SI) > 0.9.
Who cannot join
- patient's family refusal, age <18, pregnant, Patients with tachyarrhythmias, traumatic patients, patient with shock index <0.9, ischemic heart patients, any comorbidities contraindicated to take epinephrine and allergic to epinephrine will be excluded from the study.
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Ain Shams University Hospitals at Intensive care units department
Cairo, 1181
Wael Abdelmoneim, MD, +20224346344, waelelswefi@med.asu.edu.eg
About this study
Official title: Intravenous Epinephrine Bolus for Prevention of Postintubation Collapse in Intensive Care Septic Patients Predicted by Shock Index.
Endotracheal intubation is a lifesaving procedure that is performed in various settings within the hospital or even in the pre-hospital field. However, it can result in serious hemodynamic complications, such as post-intubation hypotension (PIH) and cardiac arrest. Push-dose pressor (PDP) is common practice for rapid hemodynamic correction in post-intubation hypotension. In this study the investigators will use intravenous Epinephrine bolus for prevention of post intubation collapse in septic patients predicted by shock index in intensive care unit.
Read the detailed description
- Type of Study: Randomized prospective comparative study.
- Study Setting: Ain Shams University Hospitals at Intensive care units department. • Study Period: 4 months.
- Study Population: -Inclusion Criteria: septic patients of either sex above 18 years of age, will need emergent intubation during ICU admission, shock index (SI) > 0.9.
Exclusion Criteria: patient's family refusal, age <18, pregnant, Patients with tachyarrhythmias, traumatic patients, patient with shock index <0.9, ischemic heart patients, any comorbidities contraindicated to take epinephrine and allergic to epinephrine will be excluded from the study. • Sampling Method: Study will include (44) patients who fulfill all the points in the inclusion criteria will be randomized into 2 equal groups, each consisting of (22) patients, namely group (E) and group (F). • Sample Size: 44 patients.
- Ethical Considerations: Approval of the Ethical Committee and written informed consent from all participants' legal guardians will be obtained after explanation. • Study Procedures: Push-dose epinephrine will be prepared (following mixing instructions) and administered via large bore (14-18 gauge) peripheral intravenous (IV) access. (44) Patients will randomly be assigned into two groups, (E group for epinephrine n= 22, F group for IV bolus isotonic fluid n=22). Randomization will be done using sequentially numbered, opaque, sealed envelopes containing computer generated random allocations.
In Group (E) patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased. In Group (F) patients will receive IV bolus isotonic fluid 500 ml as it is yet the standard method used before intubation.
Blood pressure, heart rate, oxygen saturation will be measured before intubation and every 5 minutes for 30-minute, lactate will be measured at intubation and 6-hour postintubation. Incidence of arrythmia will be recorded.
Primary intention will be incidence of cardiac arrest during intubation or sever hypotension (decrease > 20% of baseline mean arterial blood pressure) (Bijker et al, 2007).
Secondary intention will be incidence of arrythmias, bradycardia (heart rate < 50/minute), increased lactate, need for or increase dose of postintubation vasopressor (norepinephrine 30 ng /kg/min.) and decreased oxygen saturation.
Sample size: Data collected will be analyzed using PASS 15 program for sample size calculation, setting power 80% and alpha error at 0.05 and according to "panchal et al, 2015 ", the expected increase in SBP and DBP in epinephrine group is about 25%. Assuming no change in control group, sample size 22 patients per group will be needed to detect the difference between groups.
Statistical analysis: will be performed using computer software statistical package for the social science (SPSS, version 20; SPSS Inc., Chicago, Illinois, USA). Description of Quantitative (numerical) variables will be performed in the form of mean ± SD. Description of the qualitative (categorical) data will be performed in the form of numbers of cases and percent. Error bars represent 95% confidence interval. ANOVA test and chi-square tests will be used for comparison among different times in the same group in quantitative data. Significance level will be set at P-value of 0.05 or less, and P-value of 0.01 or less will be considered highly significant.
- Conditions
- Shock
- Being tested
- epinephrine, isotonic fluid
- Medical subject headings
- Shock
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
epinephrineDrug
patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
isotonic fluidDrug
patients will receive IV bolus isotonic fluid 500 ml
| Study group | Role | What they receive |
|---|---|---|
| E group for epinephrine | Active comparator | In Group (E) patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased. Receives: Drug: epinephrine |
| Group (F) | Placebo comparator | In Group (F) patients will receive IV bolus isotonic fluid 500 ml as it is yet the standard method used before intubation Receives: Drug: isotonic fluid |
What is being measured
The primary outcome is the main question the study is designed to answer.
incidence of cardiac arrest during intubation
cardiac arrest
Measured: during and till 30 minutes after intubation
sever hypotension
decrease > 20% of baseline mean arterial blood pressure
Measured: during and till 30 minutes after intubation
Secondary outcomes (5)
incidence of arrythmias
arrythmias
Measured: during and till 30 minutes after intubation
bradycardia
heart rate < 50/minute
Measured: during and till 30 minutes after intubation
increased lactate
more than base line
Measured: lactate will be measured 1 hour after intubation
need for or increase dose of postintubation vasopressor
norepinephrine 30 ng /kg/min.
Measured: during and till 30 minutes after intubation
decreased oxygen saturation
less than 90%
Measured: during and till 30 minutes after intubation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2023
- Study start1 Aug 2023
- Primary completionDec 2023 (estimated)
- Study completionJan 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ShockStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- : septic patients of either sex above 18 years of age, will need emergent intubation during ICU admission, shock index (SI) \> 0.9.
- Masking
- None (open label)
- Enrolment
- 44 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06115473
- Sponsor's protocol ID
- FMASU R303/2023
- Status last verified
- Oct 2023
- First submitted
- 30 Oct 2023
- Last updated
- 8 Nov 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 8 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intravenous Epinephrine Bolus for Prevention of Postintubation Collapse in Intensive Care Septic Patients Predicted by Shock Index.
- ClinicalTrials.gov ID
- NCT06115473
- Acronym / sponsor ID
- FMASU R303/2023
- Conditions
- Shock
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 44 participants (estimated)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- Dec 2023 (estimated)
- Study completion
- Jan 2024 (estimated)
- First posted
- 3 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endotracheal intubation is a lifesaving procedure that is performed in various settings within the hospital or even in the pre-hospital field. However, it can result in serious hemodynamic complications, such as post-intubation hypotension (PIH) and cardiac arrest. Push-dose pressor (PDP) is common practice for rapid hemodynamic correction in post-intubation hypotension. In this study the investigators will use intravenous Epinephrine bolus for prevention of post intubation collapse in septic patients predicted by shock index in intensive care unit.
Detailed description
- Type of Study: Randomized prospective comparative study.
- Study Setting: Ain Shams University Hospitals at Intensive care units department. • Study Period: 4 months.
- Study Population: -Inclusion Criteria: septic patients of either sex above 18 years of age, will need emergent intubation during ICU admission, shock index (SI) > 0.9.
Exclusion Criteria: patient's family refusal, age <18, pregnant, Patients with tachyarrhythmias, traumatic patients, patient with shock index <0.9, ischemic heart patients, any comorbidities contraindicated to take epinephrine and allergic to epinephrine will be excluded from the study. • Sampling Method: Study will include (44) patients who fulfill all the points in the inclusion criteria will be randomized into 2 equal groups, each consisting of (22) patients, namely group (E) and group (F). • Sample Size: 44 patients.
- Ethical Considerations: Approval of the Ethical Committee and written informed consent from all participants' legal guardians will be obtained after explanation. • Study Procedures: Push-dose epinephrine will be prepared (following mixing instructions) and administered via large bore (14-18 gauge) peripheral intravenous (IV) access. (44) Patients will randomly be assigned into two groups, (E group for epinephrine n= 22, F group for IV bolus isotonic fluid n=22). Randomization will be done using sequentially numbered, opaque, sealed envelopes containing computer generated random allocations.
In Group (E) patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased. In Group (F) patients will receive IV bolus isotonic fluid 500 ml as it is yet the standard method used before intubation.
Blood pressure, heart rate, oxygen saturation will be measured before intubation and every 5 minutes for 30-minute, lactate will be measured at intubation and 6-hour postintubation. Incidence of arrythmia will be recorded.
Primary intention will be incidence of cardiac arrest during intubation or sever hypotension (decrease > 20% of baseline mean arterial blood pressure) (Bijker et al, 2007).
Secondary intention will be incidence of arrythmias, bradycardia (heart rate < 50/minute), increased lactate, need for or increase dose of postintubation vasopressor (norepinephrine 30 ng /kg/min.) and decreased oxygen saturation.
Sample size: Data collected will be analyzed using PASS 15 program for sample size calculation, setting power 80% and alpha error at 0.05 and according to "panchal et al, 2015 ", the expected increase in SBP and DBP in epinephrine group is about 25%. Assuming no change in control group, sample size 22 patients per group will be needed to detect the difference between groups.
Statistical analysis: will be performed using computer software statistical package for the social science (SPSS, version 20; SPSS Inc., Chicago, Illinois, USA). Description of Quantitative (numerical) variables will be performed in the form of mean ± SD. Description of the qualitative (categorical) data will be performed in the form of numbers of cases and percent. Error bars represent 95% confidence interval. ANOVA test and chi-square tests will be used for comparison among different times in the same group in quantitative data. Significance level will be set at P-value of 0.05 or less, and P-value of 0.01 or less will be considered highly significant.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- : septic patients of either sex above 18 years of age, will need emergent intubation during ICU admission, shock index (SI) > 0.9.
| Arm | Type | Receives |
|---|---|---|
| E group for epinephrine | Active comparator | Drug: epinephrineIn Group (E) patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased. |
| Group (F) | Placebo comparator | Drug: isotonic fluidIn Group (F) patients will receive IV bolus isotonic fluid 500 ml as it is yet the standard method used before intubation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- septic patients of either sex above 18 years of age, will need emergent intubation during ICU admission, shock index (SI) > 0.9.
Key exclusion criteria (1 listed)
- patient's family refusal, age <18, pregnant, Patients with tachyarrhythmias, traumatic patients, patient with shock index <0.9, ischemic heart patients, any comorbidities contraindicated to take epinephrine and allergic to epinephrine will be excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| epinephrinepatients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased. | Drug | E group for epinephrine |
| isotonic fluidpatients will receive IV bolus isotonic fluid 500 ml | Drug | Group (F) |
Primary outcome
incidence of cardiac arrest during intubation
Time frame: during and till 30 minutes after intubation
cardiac arrest
sever hypotension
Time frame: during and till 30 minutes after intubation
decrease > 20% of baseline mean arterial blood pressure
5 secondary outcomes
incidence of arrythmias
Time frame: during and till 30 minutes after intubation
bradycardia
Time frame: during and till 30 minutes after intubation
increased lactate
Time frame: lactate will be measured 1 hour after intubation
need for or increase dose of postintubation vasopressor
Time frame: during and till 30 minutes after intubation
decreased oxygen saturation
Time frame: during and till 30 minutes after intubation
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Nov 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Shock
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
RecruitingObservational study
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis
Active, not recruitingPhase 3
The Danish Out-of-Hospital Cardiac Arrest Study
Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ain Shams University Hospitals at Intensive care units department
Cairo, Egypt
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing epinephrine and isotonic fluid in people with Shock, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
incidence of cardiac arrest during intubation (time frame: during and till 30 minutes after intubation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2023.